Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

10.36USD
24 Feb 2017
Change (% chg)

$0.12 (+1.17%)
Prev Close
$10.24
Open
$10.22
Day's High
$10.42
Day's Low
$10.08
Volume
313,087
Avg. Vol
411,273
52-wk High
$10.84
52-wk Low
$3.80

Select another date:

Tue, Feb 14 2017

BRIEF-Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment

* Progenics Pharmaceuticals announces initiation of a phase 1 clinical trial of its PSMA-targeted therapeutic candidate 1095 for the treatment of metastatic prostate cancer Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald

* Entered controlled equity offering sales agreement with Cantor Fitzgerald, pursuant to which Co may offer, sell up to $75 million stock Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharmaceuticals files for mixed shelf of up to $250 mln - SEC filing

* Progenics Pharmaceuticals Inc - files for mixed shelf of up to $250 million - SEC filing Source text: (http://bit.ly/2jcUEzy) Further company coverage:

BRIEF-Progenics announces $50 million RELISTOR royalty-backed financing

* Progenics announces $50 million RELISTOR royalty-backed financing

BRIEF-Valeant and Progenics announce the U.S. commercial launch of FDA-approved Relistor tablets

* Valeant and Progenics announce the U.S. commercial launch of FDA approved Relistor tablets Source text for Eikon: Further company coverage:

Progenics Pharmaceuticals whistleblower wins another $3 million

A former Progenics Pharmaceuticals Inc chemist who last year won a $1.66 million verdict from a biotechnology company accused of retaliating against him for whistleblower claims was awarded at least $3.3 million more on Tuesday.

Select another date:

More From Around the Web